The current randomized trial examined the effects of a Tibetan yoga program (TYP) versus a stretching program (STP) and usual care (UC) on sleep and fatigue in women with breast cancer who were undergoing chemotherapy. METHODS: Women with stage (American Joint Committee on Cancer (AJCC) TNM) I to III breast cancer who were undergoing chemotherapy were randomized to TYP (74 women), STP (68 women), or UC (85 women). Participants in the TYP and STP groups participated in 4 sessions during chemotherapy, followed by 3 booster sessions over the subsequent 6 months, and were encouraged to practice at home. Self-report measures of sleep disturbances (Pittsburgh Sleep Quality Index), fatigue (Brief Fatigue Inventory), and actigraphy were collected at baseline; 1 week after treatment; and at 3, 6, and 12 months. RESULTS: There were no group differences noted in total sleep disturbances or fatigue levels over time. However, patients in the TYP group reported fewer daily disturbances 1 week after treatment compared with those in the STP (difference, -0.43; 95% confidence interval [95% CI], -0.82 to -0.04 [P 5.03]) and UC (difference, -0.41; 95% CI, -0.77 to -0.05 [P 5.02]) groups. Group differences at the other time points were maintained for TYP versus STP. Actigraphy data revealed greater minutes awake after sleep onset for patients in the STP group 1 week after treatment versus those in the TYP (difference, 15.36; 95% CI, 7.25-23.48 [P 5.0003]) and UC (difference, 14.48; 95% CI, 7.09-21.87 [P 5.0002]) groups. Patients in the TYP group who practiced at least 2 times a week during follow-up reported better Pittsburgh Sleep Quality Index and actigraphy outcomes at 3 months and 6 months after treatment compared with those who did not and better outcomes compared with those in the UC group. CONCLUSIONS: Participating in TYP during chemotherapy resulted in modest short-term benefits in sleep quality, with long-term benefits emerging over time for those who practiced TYP at least 2 times a week. Cancer 2018;124:36-45.
INTRODUCTION
Although chemotherapy for breast cancer improves disease-free and overall survival, toxicities remain high and impact quality of life. 1, 2 Sleep disturbances and fatigue, often ranked as the most problematic side effects of treatment, 3, 4 are especially debilitating. Specific rates of fatigue are hard to estimate from previous studies due to different measures used and a lack of clinical specificity. Nevertheless, one cohort study of 218 women reported that at the end of treatment, 26% of the sample experienced case rates of fatigue and 16% of the sample reported case rates of fatigue plus mood disturbances. 5 Some studies also have shown only modest increases in fatigue. 6 In addition, fatigue levels do not appear to be linear in nature. For example, 2 longitudinal studies revealed that women demonstrated a marked increase in fatigue during cycle 1, which then decreased, yet peaked during cycle 4. 7, 8 The prevalence of sleep disturbance appears to be higher, with estimates ranging between 30% and 75%, 9 ,10 yet with some studies demonstrating stable levels. 7 Yoga is an effective modality with which to reduce symptoms pertaining to sleep disturbances and fatigue for cancer survivors who have completed cancer treatment. A large multicenter randomized controlled trial (RCT) involving 410 survivors (75% of whom had breast cancer) with sleep disturbances found that an 8-session yoga intervention improved both objective and subjective sleep quality compared with a group receiving usual care (UC). 11 Two smaller trials conducted in survivors of breast cancer after completing treatment, 1 of which was a single-arm study 12 and the other comparing yoga with a health education control group, 13 found that yoga was effective at reducing persistent fatigue that was maintained at 3 months after the intervention.
Although research has examined the effects of yoga delivered during chemotherapy for women with breast cancer, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] to the best of our knowledge only one study to date was designed to specifically target fatigue and none have targeted sleep outcomes. Taso et al 16 conducted a small RCT comparing yoga with UC for women with breast cancer undergoing chemotherapy and found reduced fatigue compared with UC, which demonstrated increased fatigue. Other studies have examined sleep and fatigue as secondary outcomes. Improvement in fatigue was noted in 2 small single-arm studies 21, 25 and only for within-group analyses in RCTs 22 and for those attending more yoga classes. 24 Similarly, a small RCT by Dhruva et al 14 found that the amount of yoga practice during chemotherapy was associated with decreased sleep disturbance. Our prior work of a Tibetan yoga program (TYP) for patients with lymphoma who were either undergoing treatment or within 12 months of completing treatment found that the program resulted in fewer sleep disturbances compared with a wait-list control group. 26 A subsequent trial for women with breast cancer found that TYP led to reduced sleep disturbances and fatigue 27 for women who were undergoing chemotherapy at the time of delivery of the intervention.
Previous yoga research has not typically included active control groups or long-term follow-up, thereby limiting the interpretation of the findings. The current trial was designed to address the limitations of previous studies and to further our knowledge regarding the effective management of sleep disturbances and fatigue in women with breast cancer actively receiving chemotherapy. We hypothesized that the TYP group would have lower sleep disturbances and fatigue than an active stretching program (STP) group and a UC wait-list control group (UC) because the TYP integrates physical movements with specific breathing exercises and meditative stress reduction techniques.
MATERIALS AND METHODS

Study Population
Women with stage (American Joint Committee on Cancer (AJCC) TNM) I to III breast cancer who were undergoing chemotherapy and were aged 18 years; were able to read, write, and speak English; and were scheduled to undergo neoadjuvant or adjuvant chemotherapy (weekly or every 21 days) at The University of Texas MD Anderson Cancer Center were enrolled. Patients with lymphedema, deep vein thrombosis, a documented diagnosis of a formal thought disorder (eg, schizophrenia), a score of 23 on the Mini-Mental State Examination, extreme mobility problems limiting their ability to engage in the practices (selfdefined), or those who had regularly (self-defined) practiced yoga in the year before diagnosis were excluded. The protocol was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board, and patients were recruited between 2007 and 2012.
Procedures
Women were approached either before starting or within the first 2 cycles of chemotherapy. Chemotherapy consisted of neoadjuvant or adjuvant paclitaxel given weekly for 12 cycles or every 3 weeks for 4 cycles or neoadjuvant docetaxel given every 3 weeks for 4 cycles followed by 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC)/ 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) every 3 weeks for 4 cycles. Therefore, the majority of patients completed the TYP or STP intervention sessions within the first 12 weeks of chemotherapy and before initiation of FAC/FEC. After providing written informed consent, participants completed a 60-minute baseline assessment and wore an actigraphy watch 24 hours per day for 7 days to assess sleep quality. Participants then were randomized to 1 of 3 groups (TYP, STP, or UC), using a form of adaptive randomization, minimization, 28 with age, stage of disease, time since diagnosis, baseline fatigue scores, menopausal status, type of surgical procedure, and chemotherapy treatment and regimen as randomization factors. Follow-up assessments were conducted 1 week after the end of the intervention and 3, 6, and 12 months later. Participants were given a gift certificate with a $25 value after completing each assessment. Participants in the UC group completed all assessments on the same timeline as the active groups. STP and UC group participants were offered yoga classes at the end of their study participation. All participants were asked to refrain from participating in any other yoga classes while on study or to report it if they did practice.
Intervention Programs
Participants in the TYP and STP groups attended 4 classes of 75 to 90 minutes each during their chemotherapy treatment. The majority of classes were delivered in a 1-on-1 format to meet each patient's unique schedule. Patients also were encouraged to practice daily outside of the classes at the hospital. Patients in both interventions were given printed materials, audio recordings, and a video of all the techniques. Both groups also had 3 booster sessions during follow-up. The manualized interventions are available upon request.
Tibetan yoga program
Each TYP class was taught by 1 of 4 trained instructors from the Ligmincha Texas Institute, with continuity of instructor for each patient. TYP instructors had at least 3 years of practice experience and received relevant oncology training as well as specific training for teaching the TYP protocol to patients with breast cancer.
TYP consisted of 4 main components: 1) mindfulness and focused attention through guided meditation with breathing and visualization; 2) an alternate nostril breathing practice (9 breathings of purification) and a breath retention exercise (eg, 4-part breath); 3) Tsa Lung movements; and 4) closing with a brief compassion-based meditation. Tsa Lung 26 is an ancient Tibetan contemplative practice that includes a series of 5 gentle movements involving rotations and stretches of different parts of the body coordinated with specific breathing patterns.
Stretching program
A physical therapist and an exercise physiologist taught the majority of the STP classes, with <10% of the sessions taught by a mind-body instructor, with continuity of instructor for each patient. Instructors had > 10 years of experience. STP included exercises recommended specifically for women undergoing or recovering from breast cancer treatment. 29, 30 The exercises included standing, lying down, and sitting positions and approximated the gross movements of the TYP (eg, horizontal arm stretch, breast stroke, neck stretch, and a quarterback throwing a football).
Outcome Measures
Demographic and medical data were collected and extracted from the medical records.
Primary intervention outcomes: self-report
Sleep disturbances were assessed using the Pittsburgh Sleep Quality Index (PSQI). 31 The PSQI is an 18-item self-rated questionnaire that assesses quality of sleep and sleep disturbances over a 1-month period. The scale includes 3 component subscales of sleep efficiency, perceived sleep quality, and daily disturbances, and a total score, with scores of 5 indicating clinically significant sleep disturbances. 31 Fatigue was assessed using the Brief Fatigue Inventory (BFI). 32 The BFI is a 9-item questionnaire designed to be used in the clinical setting to rapidly assess fatigue severity. The items are ranked from 0 to 10, and patients rate their fatigue at its "worst" and "usual" and as it is "now," with 0 indicating "no fatigue" and 10 indicating "fatigue as bad as you can imagine," and how much their fatigue has interfered with their life.
Secondary intervention outcomes: objective measures
Objective sleep patterns were measured with actigraphy. Participants were instructed to wear actigraphs on the wrist of their nondominant arm for 24 hours for 7 days at each study time point. Data were collected in 15-second epochs for the entire 7 days. Weekly aggregate scores for daily data are presented for measures of sleep efficiency (the percentage of time asleep during the sleep episode), onset latency (the number of minutes it takes to fall asleep), total sleep time, and wake after sleep onset (WASO) (number of minutes awake during the night after initial sleep onset).
Out-of-class practice
Out-of-class practice was encouraged for participants in the TYP and STP groups, and patients reported their outof-class practice each week during the intervention phase and then at each follow-up assessment that asked about practice during the previous week.
Data Analyses
The primary outcomes were self-reported sleep disturbances and fatigue. When the sample size in each of the 3 groups is 100, a 1-way analysis of variance will have 81% power to detect at the 0.05 level a difference in the means of each outcome characterized by a variance of means of 0.034, assuming that the common standard deviation is 1.0. As an example, the variance of means of 0.034 may be characterized by means of 0, 0.39, and 0.39, respectively, across the UC, STP, and TYP groups. Although we recognized that the power calculation was based on 1 outcome at 1 time point (specifically, 1 week after the intervention), with a significance level of 0.05, we considered it appropriate to make a Bonferroni adjustment for the analyses of the PSQI and BFI total scores to reduce inflated type I errors, yielding an alpha level of .025 for each outcome. Main analyses were based on observed data from women who were randomized and met the study eligibility criteria, and were performed with multilevel modeling using PROC MIXED (9.2.2 version; SAS Institute Inc, Cary, NC). These analyses allowed between-group comparisons of the outcomes of interest, not only across time points but also at specific time points as post hoc analyses, when desirable. We assumed a random intercept in the model, and randomization factors were entered as a priori covariates in all main analyses (stage of disease, type of surgery, chemotherapy regimen, timing of chemotherapy, menopausal status, age, and time since diagnosis). Time point was treated as a categorical variable. We examined the group main effect while controlling for baseline scores of the outcome. For the secondary outcomes of PSQI subscales and actigraphy, we used a conventional alpha level at .05. CONTRAST statements were used within the mixed procedure to test for group differences. If there was no significant group main effect or contrast comparison effect noted, we then examined the interaction of the group multiplied by the time using CONTRAST statements to determine whether there were significant group differences at a given time point and reported on the effect size estimates. Model assumptions were examined by plotting histograms and quantilequantile plots of the studentized residuals from the mixed models. In the event model assumptions were not met, a log or square root transformation was applied, as appropriate, with the corresponding results briefly summarized, yet with the untransformed data being presented for the results to be comparable to those in the literature.
RESULTS
Baseline Characteristics of Sample
We approached 933 potentially eligible patients (Fig. 1) , of whom 132 were ineligible, 349 refused participation, and 452 consented. Of those, 352 patients completed baseline measures and were randomized. Of those patients randomized, 54 had completed chemotherapy at baseline and 71 did not provide any follow-up data, resulting in an evaluable sample of 227 participants. The dropout rate was similar in each group. Chi-square and Student t tests comparing baseline demographic and medical characteristics and outcome measures of study completers versus noncompleters demonstrated no significant differences, with the exception of PSQI total score (F value, 4.26; P 5 .04); completers had lower PSQI scores (less sleep disturbance) compared with noncompleters. Activity monitor data were missing for 31% of participants (71 participants) who returned questionnaires. No significant group differences were found with regard to demographic and medical factors ( Table 1) or any of the baseline study variables. There were no group differences noted based on when patients underwent surgery compared with their participation in the study (11.5% before, 52.0% during, and 36.6% after).
Completion of Interventions
A total of 54 participants (73% of the baseline sample) completed all 4 TYP sessions, 6 completed 3 sessions, 5 completed 2 sessions, and 8 completed only 1 session. Of the STP participants, 50 (74% of the baseline sample) completed all 4 sessions, 7 completed 3 sessions, 5 completed 2 sessions, and 5 completed only 1 session. Approximately 63% of the participants in the TYP group said they practiced 2 times a week 1 week after the end of the program, as did 38.3% at 3 months, 41.3% at 6 months, and 20.5% at 12 months. STP participants reported high levels of practice at each follow-up time point: 69.4% at 1 week and 45.4% at 3 months, 61.5% at 6 months, and 50.0% at 12 months. Adherence to the booster sessions was lower for both groups. Of the 74 participants in the TYP group, 51% did not have any booster classes, 24% had 1 booster class, 16% had 2 booster classes, and 8% had all 3 booster classes. Of the 68 participants in the STP group, 43% did not have any booster classes, 31% had 1 booster class, 12% had 2 booster classes, and 15% had all 3 booster classes. There were no significant group differences noted with regard to class attendance or frequency of practice during the follow-up time period. There were no adverse events found to be associated with either intervention.
Intervention Efficacy
Sleep disturbances
Although there was a significant time main effect (F value, 11.52; P<.0001) with a decrease in sleep disturbances over time, the group main effect (F value, 1.86; P 5 .16) Original Article and the group multiplied by time interaction (F value, 0.25; P 5 .96) for the PSQI total score were not significant (Table 2 ). There was a significant group main effect for daily disturbances (F value, 4.89; P 5 .008), with the TYP group reporting lower scores than participants in the Figure  2 , demonstrating that group differences between TYP and STP remained over time. The main effects, time multiplied by group interactions, and contrast comparisons were not significant for sleep efficiency, perceived sleep quality, or use of sleep medications. Effect size estimates for the 1-week follow-up time point are presented in Table 3 .
Fatigue
There was a significant main effect of time (F value, 19.19; P<.0001), with significant increases in fatigue observed at the 1-week and 3-month time points and returning to baseline at 6 months and 12 months (Table  2) . However, the group main effect (F value, 0.12; P 5 .89), contrast comparisons, and the group multiplied by time interaction (F value, 0.49; P 5 .82) were not significant.
Actigraphy
Although the group main effect was not significant, there was a significant group multiplied by time interaction for WASO (F value, 2.50; P 5 .03 Table 2 ). The histograms of studentized residuals from the mixed models for WASO and sleep efficiency appeared slightly rightskewed and left-skewed, respectively. A log and a square root transformation thus were applied to each of the outcomes, respectively, resulting in approximate normality of the residuals. After the log transformation for WASO, the group multiplied by time interaction became nonsignificant, with the 1-week outcomes remaining the same. The outcomes remained the same for sleep efficiency after a square root transformation was applied. There was no group main effect or group multiplied by time interaction for sleep latency and total sleep time, and no contrast comparisons were significant. Effect size estimates for the 1-week follow-up time point are presented in Table 3 .
Class Attendance and Out-of-Class Practice
Exploratory analyses examined the association between class attendance and out-of-class practice and outcomes, covarying for baseline. The number of classes attended Although there were no group differences noted between participants with and without missing data regarding demographic, medical, or the outcome variables at baseline (except for PSQI total score), we imputed 20 values for the missing data using multiple imputations (V9.2 MI procedure; SAS Institute Inc) with the Markov chain Monte Carlo method and then used the MIANA-LYZE procedure to generate statistical inferences. All the analyses remained the same or resulted in similar P values.
DISCUSSION
We examined a TYP program targeting sleep disturbance and fatigue in women undergoing chemotherapy for breast cancer. Group differences mainly emerged when comparing TYP with STP, suggesting that the STP participants had worse daily sleep disturbances than TYP participants and more minutes being awake after sleep onset (WASO) than both TYP and UC participants, who did not differ from each other except with regard to daily sleep disturbances at the end of the program, with the differences disappearing over time. However, there were no statistically significant group differences noted for the primary outcomes of total sleep disturbance and fatigue, thereby limiting the clinical significance of the findings. Sleep disturbance scores remained in the clinically significant range over time and fatigue levels did increase significantly during treatment, but then returned to baseline levels by the 6-month and 12-month time points. However, it was found that patients who reported practicing TYP 2 times a week did have better sleep outcomes than those who did not and better sleep outcomes compared with those in the UC group 3 months and 6 months after the program, with medium to large effect sizes.
A reason for the modest effects of TYP noted in the current study compared with our past studies and those of others examining the effects of yoga may be due to the frequency of instruction and the timing of instruction. In our prior studies of a similar TYP, 26 our work with Tibetan yoga for patients with lung cancer and their caregivers, 33 and our Indian-based yoga research, the patientinstructor contact varied from a low of 7 weekly 60-minute sessions 26 up to 18 sessions of 60 minutes each (3 times a week for 6 weeks). 34 In the current trial, patients attended a maximum of 4 sessions of 90 minutes each. The original trial design was to deliver 7 weekly 60-minute sessions over 7 weeks. However, due to the fact that many patients started to receive paclitaxel every 3 weeks instead of weekly, it became impractical to conduct weekly sessions due to patients not wanting to come to the hospital for their sessions. Future research ideally should have a minimum of 6 weekly sessions so there is some continuity of practice. If shorter exposure is necessary, then it is critical to ensure that patients are willing to engage in the practices outside of class to enhance the benefits and provide them with home-based support.
In fact, we did find that those patients who engaged in the TYP 2 times per week did have better sleep outcomes. This finding is consistent with other yoga studies that found the frequency of practice was associated with better outcomes. 14, 24, 25 Although to our knowledge the minimum frequency of yoga practice with which to achieve positive benefits has yet to be determined, it generally is believed that daily practice is ideal. Future studies should examine methods to increase practice frequency outside of class, including reminders for practice, engaging local practitioners for convenient booster sessions, and exploring the delivery of yoga classes via mobile technologies.
Although we hypothesized that the TYP would result in better outcomes than STP and UC, it was found that TYP was mainly better than STP, with only 1 outcome noted to be different from UC. The differences between STP and TYP/UC mainly were due to the fact that the STP group did not get better over time, as was noted with the other 2 groups. It remains unclear why simple stretching exercises would slow down improvement in sleep outcomes after chemotherapy compared with usual care. Chart reviews did not offer any clues.
There are several limitations to the current study. Recruiting patients undergoing chemotherapy was challenging, resulting in a 56% participation rate. Moreover, approximately 22% of patients dropped out of the study before randomization and another 20% did not provide any follow-up data and therefore were not included in the analyses. However, we noted that there were no systematic differences with regard to any factors between those patients who provided follow-up data or were lost to follow-up, thereby diminishing concerns of a biased sample. The high rate of attrition may have resulted in the trial being underpowered. However, it is unlikely that a larger sample size would have changed the findings. The current study also was a single-center study with a relatively homogeneous patient population. The patient-instructor encounter time also was limited and this may have been the main reason for the lack of benefit noted when comparing TYP with UC. In addition, the classes were delivered in a 1-on-1 format, thereby removing the possible benefits derived from teaching yoga in a group format in which participants receive social support. Although the current study was not a priori powered to detect clinically significant group differences, the majority of group differences were classified as medium to large effects. In addition, due to the exclusion of the 54 patients who were not receiving treatment during the trial, the current analyses were not entirely consistent with the intent-to-treat principle. Instead, the current study should be deemed a per-protocol analysis based on women who were randomized and met the study eligibility criteria. The current trial also was not conducted in a blinded manner with regard to the group assignment. Because there were 2 active intervention groups, participants could have been informed that we were testing 2 different behavioral interventions to improve aspects of quality of life. In this way, participants would not have known the details of each intervention group and patients in both groups would have believed they were receiving the active intervention. This is the model the study laboratory and others currently are using for mind-body research. However, at the time the current study was launched, this innovative approach was not being used. We also did not inquire regarding expectations of the benefits of the interventions programs, which could have influenced outcomes.
Even with the limitations of the current study, it is interesting to note that there were some modest short-term benefits associated with TYP, even though patients attended only up to 4 in-person sessions spread over 4 to 12 weeks. It also is encouraging to note that the frequency of practice outside of class was associated with improved sleep outcomes over time. The findings of the current study suggest that it is ideal to have >4 in-person sessions to improve patient outcomes, whereas to our knowledge the minimum dose necessary to improve outcomes was previously unknown. Future research using shorter in-class instruction exposure should focus on increasing patient engagement in the practices after leaving the formative instructional portion of the intervention.
